SOLIDARITY TRIAL PLUS: An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care

An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18066414

Enrollment

10000

Registered

2021-07-29

Start date

2021-08-02

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care Infections and Infestations COVID-19 (SARS-CoV-2 infection)

Interventions

Once electronic data collection has been completed the patient automatically enters the trial and a random allocation of their trial treatment is generated (by an algorithm that ensures eventual balan

IV injection

duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria 2. Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard d

orally once daily

duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies Follow-up: All randomised

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: The only patients invited will be those admitted to a collaborating hospital; no wider recruitment is expected. 1. Adults (age =18 years, which allows consent) 2. Recently hospitalized (or already in hospital) with laboratory-confirmed COVID 3. Not expected to be transferred within 72 hours 4. With, in the view of their doctors, no contra-indication to any potentially relevant study drug

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
In-hospital mortality in all patients measured using patient records up to the end of hospital stay	—

Secondary

Measure	Time frame
Measured using patient records: 1. Initial respiratory support (yes/no) 2. Initiation of ventilation in lower-risk patients (yes/no) 3. Duration of hospital stay (days)	—

Countries

Albania, Argentina, Bangladesh, Botswana, Brazil, Canada, Colombia, Dominican Republic, Egypt, Ethiopia, Finland, Honduras, India, Ireland, Kenya, Latvia, Lebanon, Lithuania, Malaysia, Mali, Mozambique, Nepal, Nigeria, North Macedonia, Pakistan, Panama, Paraguay, Philippines, Portugal, Switzerland, Tunisia, Zimbabwe

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 25, 2026